Literature DB >> 6203936

The neuroleptic syndrome and central dopamine metabolites.

G D Tollefson, M J Garvey.   

Abstract

The neuroleptic malignant syndrome remains an intriguing syndrome, yet its pathogenesis is unknown. Despite numerous analogies with peripheral disorders of aberrant calcium migration in the sacroplasmic reticulum, the probable loci are striatal and hypothalamic (preoptic) dopaminergic pathways. In order to clarify the characteristics of dopamine activity, analysis of the central metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid in one case revealed marked elevations. A possible role for postsynaptic dopamine receptor inhibition is discussed. These findings further suggest that the syndrome may be similar to other extrapyramidal disorders, and they lend credence to observations of its reported drug induction and management.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203936

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

1.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

2.  The muscle findings in the neuroleptic malignant syndrome associated with lysergic acid diethylamide.

Authors:  W M Behan; A M Bakheit; P O Behan; I A More
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 3.  Aetiology and treatment of neuroleptic malignant syndrome.

Authors:  C Harpe; A Stoudemire
Journal:  Med Toxicol       Date:  1987 May-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.